title: Current prophylactic and therapeutic uses of a recombinant Lactococcus lactis strain secreting biologically active interleukin-12.
abstract: The noninvasive and food-grade Gram-positive bacterium Lactococcus lactis is well adapted to deliver medical proteins to the mucosal immune system. In the last decade, the potential of live recombinant lactococci to deliver such proteins to the mucosal immune system has been investigated. This approach offers several advantages over the traditional systemic injection, such as easy administration and the ability to elicit both systemic and mucosal immune responses. This paper reviews the current research and advances made with recombinant L. lactis as live vector for the in situ delivery of biologically active interleukin-12, a potent pleiotropic cytokine with adjuvant properties when co-delivered with vaccinal antigens, at mucosal surfaces. Three well-illustrated examples demonstrate the high potential of interleukin-12-secreting lactococci strains for future prophylactic and therapeutic uses.
authors.affiliation: Unité d'Ecologie et de Physiologie du Système Digestif, INRA, Jouy-en-Josas, France. luis.bermudez@jouy.inra.fr
authors.forename: Luis G
authors.initials: LG
authors.lastname: Bermúdez-Humarán
authors.forename: Naima G
authors.initials: NG
authors.lastname: Cortes-Perez
authors.forename: Sandrine
authors.initials: S
authors.lastname: Ah-Leung
authors.forename: François
authors.initials: F
authors.lastname: Lefèvre
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Pang
authors.forename: Changyi
authors.initials: C
authors.lastname: Wu
authors.forename: Yinming
authors.initials: Y
authors.lastname: Zeng
authors.forename: Karine
authors.initials: K
authors.lastname: Adel-Patient
authors.forename: Philippe
authors.initials: P
authors.lastname: Langella
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D001249:Asthma / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D005822:Genetic Vectors; D052162:Human papillomavirus 16; D006967:Hypersensitivity / Q000209:etiology / Q000628:therapy*; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology*; D013294:Lactococcus lactis / Q000235:genetics*; D007782:Lactoglobulins / Q000009:adverse effects / Q000276:immunology; D051379:Mice; D009092:Mucous Membrane / Q000382:microbiology; D009856:Oncogene Proteins, Viral / Q000235:genetics; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
chemical_list: D007782:Lactoglobulins; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D014614:Vaccines, Synthetic; C059731:oncogene protein E7, Human papillomavirus type 16; D018664:Interleukin-12